Journal of Korean Medical Science · 2011 · 36 citations · 10 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMedical MicrobiologyMycologyAntifungal AgentsAntifungal PharmacotherapyAntifungal ResistanceAntifungal TherapyFungal InfectionsFungal PathogenesisAntifungal TreatmentsCandida Albicans InfectionCandidiasis Drug ResistanceInvasive Candidiasis TreatmentInvasive Fungal InfectionsInvasive InfectionNon-albicans Candida SpeciesTreatment Regimen Modification
Candida haemulonii, one of the non-albicans Candida species, is an emerging yeast pathogen that is known to be resistant to amphotericin B and other antifungal agents such as azoles. These anti-fungal agents have often been associated with clinical treatment failure, so no treatment regimen has been clearly established for invasive C. haemulonii infections. We investigated a catheter-related infection of C. haemulonii candidemia in an adult patient in long-term hospital care. In the early stages, the candidemia remained persistent despite treatment with fluconazole. However, after changing the antifungal agent to caspofungin, the candidemia was resolved. Fluconazole and amphotericin B are not reliable empirical antifungal agents for invasive C. haemulonii infections, as shown in previous case reports. An echinocandin such as caspofungin may be an appropriate empirical choice of antifungal agent for an invasive C. haemulonii infection.
10
The Medical Journal of Australia · 1999 · 3.4K citations
Mi‐Na Kim, Jong Hee Shin, Heungsup Sung et al. · Clinical Infectious Diseases · 2009 · 304 citations · Full text
Zia U. Khan, Noura Al‐Sweih, Suhail Ahmad et al. · Journal of Clinical Microbiology · 2007 · 103 citations · Full text